−1.8708USD
−14.88 MUSD
4.83 M
About Alzamend Neuro, Inc.
Sector
CEO
Stephan Jackman
Headquarters
Atlanta
Website
Employees (FY)
4
Founded
2016
ISIN
US02262M4078
FIGI
BBG00ZMXG7M8
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ALZN is 0.6755 USD — it has decreased by 2.24% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alzamend Neuro, Inc. stocks are traded under the ticker ALZN.
Alzamend Neuro, Inc. is going to release the next earnings report on Jul 3, 2024. Keep track of upcoming events with our Earnings Calendar.
ALZN stock is 9.58% volatile and has beta coefficient of 0.77. Check out the list of the most volatile stocks — is Alzamend Neuro, Inc. there?
One year price forecast for Alzamend Neuro, Inc. has a max estimate of 21.0000 USD and a min estimate of 21.0000 USD.
ALZN earnings for the last quarter are −0.44 USD per share, whereas the estimation was −0.52 USD resulting in a 15.38% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Alzamend Neuro, Inc. earnings.
Yes, you can track Alzamend Neuro, Inc. financials in yearly and quarterly reports right on TradingView.
ALZN stock has fallen by 24.94% compared to the previous week, the month change is a 35.05% fall, over the last year Alzamend Neuro, Inc. has showed a 93.17% decrease.
ALZN net income for the last quarter is −2.66 M USD, while the quarter before that showed −2.91 M USD of net income which accounts for 8.38% change. Track more Alzamend Neuro, Inc. financial stats to get the full picture.
Today Alzamend Neuro, Inc. has the market capitalization of 4.74 M, it has decreased by 3.19% over the last week.
No, ALZN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALZN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alzamend Neuro, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 4.00 employees. See our rating of the largest employees — is Alzamend Neuro, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alzamend Neuro, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alzamend Neuro, Inc. stock shows the sell signal. See more of Alzamend Neuro, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Alzamend Neuro, Inc. future price: according to them, ALZN price has a max estimate of 21.00 USD and a min estimate of 21.00 USD. Read a more detailed Alzamend Neuro, Inc. forecast: see what analysts think of Alzamend Neuro, Inc. and suggest that you do with its stocks.